115 results on '"Yeung, David T."'
Search Results
2. Diagnostic genomic analysis is prognostic in AYA patients with ALL treated on an MRD-stratified pediatric protocol
3. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia
4. Supporting discovery and development of medical countermeasures for chemical injury to eye and skin
5. The Kv7 Modulator, Retigabine, is an Efficacious Antiseizure Drug for Delayed Treatment of Organophosphate-induced Status Epilepticus
6. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia
7. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease
8. Screening for Efficacious Anticonvulsants and Neuroprotectants in Delayed Treatment Models of Organophosphate-induced Status Epilepticus
9. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib
10. Asciminib is a novel inhibitor of ABL1 and ABL2 gene fusions in ALL but requires the ABL SH3 domain for efficacy
11. Precision medicine approaches may be the future for CRLF2 rearranged Down Syndrome Acute Lymphoblastic Leukaemia patients
12. Evaluating the broad-spectrum efficacy of the acetylcholinesterase oximes reactivators MMB4 DMS, HLö-7 DMS, and 2-PAM Cl against phorate oxon, sarin, and VX in the Hartley guinea pig
13. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease
14. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study
15. Kinetic analysis of oxime-assisted reactivation of human, Guinea pig, and rat acetylcholinesterase inhibited by the organophosphorus pesticide metabolite phorate oxon (PHO)
16. IDH-mutant myeloid neoplasms are associated with seronegative rheumatoid arthritis and innate immune activation
17. ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure
18. Lineage-specific detection of residual disease predicts relapse in patients with chronic myeloid leukemia stopping therapy
19. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
20. A novel sulfur mustard (HD) vapor inhalation exposure system for accurate inhaled dose delivery
21. A comprehensive evaluation of the efficacy of leading oxime therapies in guinea pigs exposed to organophosphorus chemical warfare agents or pesticides
22. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
23. Clinical Outcomes of Chronic Myeloid Leukaemia (CML) Patients on Asciminib through the Managed Access Program (MAP) in Australia
24. Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
25. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study
26. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML
27. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
28. Molecular methods in diagnosis and monitoring of haematological malignancies
29. High Incidence of Secondary Malignancy after Allogeneic Hematopoietic Stem Cell Transplant in Adults: A Call for Surveillance
30. Clonal Architecture of Donor-Derived Myeloid Neoplasms after Allogeneic Hematopoietic Stem Cell Transplant
31. Age-Related Clonal Hematopoiesis Mutations Detected at the Time of Stopping Tyrosine Kinase Inhibitor Therapy Predict the Achievement of Treatment-Free Remission for Patients with CML
32. Suppression of KRAS and CBL Mutations and Hematological Improvement By Lenzilumab and Azacitidine Treatment in Proliferative Chronic Myelomonocytic Leukemia
33. Synergy of Ruxolitinib and Carfilzomib in Targeting the PAX5::JAK2 fusion I n Vitro: Potential Therapeutic Advantage for a Subset of Ph-like Acute Lymphoblastic Leukemia
34. Cytokine and Mutation Profiling Reveal Patterns of Complete Remission Rates with Lenzilumab Combination Therapy in Chronic Myelomonocytic Leukemia
35. Lenzilumab in Addition to Azacitidine Improves Complete Response Rates in Chronic Myelomonocytic Leukemia
36. Improved MRD Negativity Rates in Adverse Genomic Risk B-ALL Patients with Chemotherapy / Blinatumomab Induction: Experience from the Australasian Leukaemia Lymphoma Group (ALLG) ALL06/09 Studies
37. Asciminib Is Effective Against ABL1 Gene Fusions in Acute Lymphoblastic Leukemia but Only When the ABL1 SH3 Domain Is Present
38. High Prevalence of IDH Mutation in Myeloid Neoplasm with Concomitant Autoimmune Rheumatic Disorders
39. Single-Hit TP53mut Is Associated with Poor Outcomes in Therapy-Related but Not De Novo Myelodysplastic Syndromes: Importance of Clinical History
40. Excellent Early and Major Molecular Responses Observed with Asciminib Treatment for CP-CML: Results from the ALLG CML13 Ascend-CML Study
41. Comparison of World Health Organization and International Consensus Classification Guidelines for Myeloid Neoplasms Harboring TP53-Mutations Using an Independent International Cohort
42. Clinical Effectiveness of Conjugate Pneumococcal Vaccination in Hematopoietic Stem Cell Transplantation Recipients
43. 309 - Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Vs Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
44. 177 - Outcomes of ABO Incompatible Allogeneic Haematopoietic Stem Cell Transplant: A Single-Centre Retrospective Cohort Review
45. Modeling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission
46. TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome
47. Personalized Prediction Model to Risk Stratify Patients with Therapy-Related Myeloid Neoplasms
48. Comparable Survival Following Allogeneic Haematopoietic Stem Cell Transplant Utilising HLA-Matched Versus Alternative Donors: A Single-Centre Retrospective, Consecutive Cohort Analysis
49. Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML
50. PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.